Matrix metalloproteinase-9 MMP

Gehrmann, M., Briknarova, K., Banyai, L., Patthy, L., and Llinas, M. (2002). The col-1 module of human matrix metalloproteinase-2 (MMP-2) Structural/functional relatedness between gelatin-binding fibronectin type II modules and lysine-binding kringle domains. Biol. Chem. 383, 137-148. 

Tumor eells ean also present by themselves new MHC elass I-restricted peptides by cross-presentation, a feature believed to be unique of dendritic cells. A peptide derived from secreted matrix metalloproteinase-2 (MMP-2) is presented by melanoma cells, and the presentation is dependent on the enzyme secretion in the extracellular space, followed by uptake of exogenous MMP-2 through endocytosis mediated by integrin avPs. The process involves transfer of MMP-2 from the endocytic compartment to the cytosol and processing by the proteasome, because presentation of this peptide was blocked by proteasome inhibitors [298]. 

Stearns, M. E., and Steams, M., Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol. Res. 8, 63-67 (1996). 

V6. Vuoristo, M. S., Kellokumpu-Lehtinen, P., Parvinen, L. M., Hahka-Kemppinen, M., Korpela, M., Kumpulainen, E., and Laine, S., Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol. 39, 877-879 (2000). Walsh, K. M., Timms, P., Campbell, S., MacSween, R. N., and Morris, A. J., Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloprotei-nases-1 and-2 (TlMP-1 and TlMP-2) as noninvasive markers of hver disease in chronic hepatitis C Comparison using ROC analysis. Dig. Dis. Sci. 44, 624-630 (1999). 

Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 (MMP-2) is required for the switch to the angiogenic phenotype in a novel tumor model. Proc Natl Acad Sci USA 2000 97 3884-3889. 

As mentioned above, tumor-associated MMPs have been an interesting enzyme species for designing triggered and responsive nanocarrier systems. A bio-responsive cisplatin (CDDP] delivery system with a self-assembling peptide amphiphile (PA] constituting a cell-adhesive matrix metalloproteinase-2 (MMP-2]-sensitive... 

Extended biological investigations concerning structure-function studies were further initiated to evaluate the abilities of these clusters to inhibit Con A-induced membrane type-1-matrix metalloproteinase (MTl-MMP)-mediated pro-MMP-2 activation, cell death, and antiproliferative property in mesenchymal stromal cells (MSC).83... 

At the two lower concentrations, the orange color of methyl orange was confined to the top of the GPG spin column and with increasing concentrations the orange color moved down the column towards the top of the spin column frit, consistent with the ESI-MS intensity observations. Similar dose response titration studies have been reported with stronger binders, e.g., matrix metalloproteinase-1 (MMP-1) protein with a substituted hydroxyamide WY252 with an IC50 of 9.9 pM (see Fig. 2.7) [15]. 

Hickey M, Higham J, Sullivan M, Miles L, Fraser IS. Endometrial bleeding in hormone replacement therapy users preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 2001 75(2) 288-96. 

Caenazzo, C., Onisto, M., Sartor, L., Scalerta, R., Giraldo A., Nitti, D. and Garbisa, S. (1998). Augmented membrane type 1 matrix metalloproteinase (MTl-MMP) MMP-2 messenger RNA ration in gastric carcinomas with poor prognosis. CUn. Cancer Res. 4, 2179-2186. 

Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J Cell Physiol 221(2) 402-411. doi 10.1002/... 

Markers of systemic inflammation (e.g., C-reactive protein [CRP] and interleukin-6 [IL-6]) have been proposed to be nontradi-tional risk factors for cardiovascular disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of atherosclerotic plaque rupture, which raises the possibility of the use of MMP-9 levels as a marker for future MI or UA. In vitro and animal studies suggest that thiazolidinediones can reduce the expression of these markers. Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk. The management of UA and NSTEMI is covered in detail in Chap. 16. 

Takahashi, K., Goomer, R.S., Harwood, F., Kubo, T., Hirasawa, Y., Amiel, D. 1999. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-lbeta(lL-lbeta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthr. Cartil 7(2), 182-190. 

---